Pharmaceutical giant Eli Lilly has signed a new five-year agreement with Thermo Fisher Scientific which could cut pharmaceutical jobs in America.
As part of the deal, by summer 2010 the Fisher Clinical Services business of Thermo Fisher will be taking responsibility for Eli Lilly’s in-house clinical trial materials manufacturing, packaging and labelling operations. Not only this, but by the end of 2010, Fisher Clinical Services will handle the distribution of clinical trial materials for Lilly throughout North America.
Speaking of the move, Ralph Lipp, PhD, Vice President of Pharmaceutical Sciences Research and Development for Lilly, said, “Transitioning work like the manufacturing, packaging and labeling of clinical trial materials to Fisher Clinical Services helps us also reach Lilly’s corporate goals of reducing the costs of drug development and speeding innovative medicines to patients.”
As a result of this agreement, Lily is to cut approximately 115 pharmaceutical jobs from it’s workforce. Those employees effected will be given the opportunity to apply for pharmaceutical jobs with Fisher Clinical Services.